Search Results 1231-1240 of 21997 for Inhibition

1. FT819 in Subjects With B-cell Malignancies - Mayo Clinic

   For subjects with Philadelphia-chromosome positive (Ph+) disease, failure or intolerance to a tyrosine kinase inhibitor therapy-containing regimen. ALL ...

2. EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx - Mayo Clinic

   Interferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks prior to enrollment. Known brain metastases, unless these metastases ...

3. Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (MACS-1) - Mayo Clinic

   Ongoing treatment with an ACE-inhibitor that is considered as the potential cause of a subject's cough or requiring treatment with an ACE-inhibitor during ...

4. A Study to Provide Expanded Access for the Treatment of Cancers with Rearranged During Transfection (RET) Activation - Mayo Clinic

   Participation eligibility · Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor. · Given the nature and objectives of this EAP, ...

5. A Study of NB003 in Patients With Advanced Malignancies - Mayo Clinic

   inhibitors or inducers of CYP3A4. 5. Patients currently receiving acid-reducing agents and are unable to stop use at least 2 weeks prior to the first dose ...

6. Integrated Microfluidics and Microsensors: Yuguang Liu - Mayo Clinic Research

   For example, the overall response rate of immune checkpoint inhibitors (e.g., anti-PD1/PD-L1) is only 10% to 30%. Even in most initial responders, drug ...

7. Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older - Mayo Clinic

   Patients who are unwilling or unable to refrain from using hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins) starting 5 days before ...

8. A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis - Mayo Clinic

   Strong inhibitors of CYP1A2 (Cytochrome P450 family 1 subfamily A member 2) (example: fluvoxamine or enoxacin); Moderate inducers of CYP1A2 (limited to ...

9. A 52-week Study Of Rilzabrutinib Efficacy And Safety Compared To Placebo In Adults Diagnosed With IgG4-related Disease - Mayo Clinic

   * Prior participation in any rilzabrutinib studies or other BTK inhibitor studies. * History of treatment with an investigational drug within 6 months or 5 ...

10. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

    ... inhibitors or inducers and who are unwilling or unable to change to antiretroviral therapies without such interactions are ineligible because of the ...